Shares of BioTime, Inc. (NYSEMKT:BTX) have been assigned a consensus recommendation of “Hold” from the six research firms that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $5.33.

A number of research firms recently commented on BTX. BidaskClub lowered shares of BioTime from a “sell” rating to a “strong sell” rating in a research report on Monday. ValuEngine lowered shares of BioTime from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Zacks Investment Research raised shares of BioTime from a “hold” rating to a “buy” rating and set a $3.50 target price on the stock in a report on Tuesday, July 18th. Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $6.50 target price (up from $6.00) on shares of BioTime in a report on Monday, June 19th. Finally, Raymond James Financial, Inc. initiated coverage on shares of BioTime in a report on Friday, March 31st. They issued an “outperform” rating and a $6.00 target price on the stock.

BioTime (NYSEMKT:BTX) traded down 1.01% during mid-day trading on Monday, reaching $2.94. 229,540 shares of the company were exchanged. BioTime has a 12-month low of $2.67 and a 12-month high of $4.01. The stock has a market capitalization of $325.97 million, a price-to-earnings ratio of 3.04 and a beta of 1.37. The company’s 50 day moving average price is $3.10 and its 200-day moving average price is $3.21.

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in BioTime by 15.1% in the first quarter. Vanguard Group Inc. now owns 3,146,178 shares of the biotechnology company’s stock worth $10,855,000 after buying an additional 413,073 shares during the last quarter. State Street Corp increased its stake in BioTime by 9.3% in the fourth quarter. State Street Corp now owns 1,045,826 shares of the biotechnology company’s stock worth $3,775,000 after buying an additional 89,189 shares during the last quarter. Geode Capital Management LLC increased its stake in BioTime by 159.5% in the first quarter. Geode Capital Management LLC now owns 1,043,378 shares of the biotechnology company’s stock worth $3,599,000 after buying an additional 641,358 shares during the last quarter. Bank of New York Mellon Corp increased its stake in BioTime by 17.5% in the first quarter. Bank of New York Mellon Corp now owns 445,031 shares of the biotechnology company’s stock worth $1,535,000 after buying an additional 66,195 shares during the last quarter. Finally, Family Management Corp increased its stake in BioTime by 20.3% in the first quarter. Family Management Corp now owns 138,371 shares of the biotechnology company’s stock worth $477,000 after buying an additional 23,371 shares during the last quarter.

WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/07/24/biotime-inc-nysemktbtx-receives-average-recommendation-of-hold-from-analysts.html.

BioTime Company Profile

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Receive News & Ratings for BioTime Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc. and related companies with MarketBeat.com's FREE daily email newsletter.